SAMSUNG PHARM. CO.,

A001360
End-of-day quote. End-of-day quote  - 11/30
3865KRW +2.11%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2014 2015 2016 2017 2018
Net sales1 30 28842 16547 19441 91946 484
EBITDA1 -18 347608-2 060-3 859-1 635
Operating profit (EBIT)1 -19 820-1 870-6 327-7 774-5 399
Operating Margin -65,4%-4,44%-13,4%-18,5%-11,6%
Pre-Tax Profit (EBT)1 -23 748-654-17 348-10 966-2 016
Net income1 -23 748-994-21 618-7 540-2 076
Net margin -78,4%-2,36%-45,8%-18,0%-4,47%
EPS2 -1 304-39,0-660-189-40,5
Dividend per Share -----
Last update 03/18/201603/17/201703/20/201803/19/201903/19/2019
1 KRW in Million
2 KRW
Finances - Leverage
Fiscal Period: December 2014 2015 2016 2017 2018
Net Debt1 22 92035 18331 77418 710-
Net Cash position1 ----14 955
Leverage (Debt / EBITDA) -1,25x57,8x-15,4x-4,85x9,14x
Free Cash Flow --16 091-41 611-4 883-16 402
ROE (Net Profit / Equities) --2,86%-26,8%-8,25%-1,84%
Shareholders' equity1 -34 76680 73991 345112 767
ROA (Net Profit / Asset) --1,25%-2,95%-3,32%-2,14%
Assets1 -79 800733 969226 93496 833
Book Value Per Share2 1 0211 6792 0762 2682 263
Cash Flow per Share2 13771113670,854,2
Capex1 2 09011 86233 2366 1082 614
Capex / Sales 6,90%28,1%70,4%14,6%5,62%
Last update 03/18/201603/17/201703/20/201803/19/201903/19/2019
1 KRW in Million
2 KRW
Balance Sheet Analysis
Price Earning Ratio
EPS & Dividend